Yes, hemochromatosis can be fatal if it goes undiagnosed and untreated. The condition causes iron to accumulate in organs over years or decades, eventually leading to liver failure, heart failure, or liver cancer. The good news: patients diagnosed before serious organ damage occurs and treated with regular blood removal have a normal life expectancy.
How Iron Overload Becomes Life-Threatening
Your body has no natural way to get rid of excess iron. In hemochromatosis, iron keeps absorbing from food and building up in tissues, particularly the liver, heart, and pancreas. At the cellular level, this excess iron reacts with hydrogen peroxide inside cells, generating molecules that damage cell membranes and disrupt normal cell function. Over time, cells die and scar tissue replaces healthy tissue.
This process is slow. Most people don’t develop symptoms until their 40s or 50s, by which point iron may have been accumulating for decades. The damage is cumulative and, in some organs, irreversible.
The Three Leading Causes of Death
A study tracking 163 hemochromatosis patients identified the specific conditions most likely to prove fatal. Liver cancer was 219 times more frequent as a cause of death than in the general population. Cardiomyopathy (heart muscle disease from iron deposits) was 306 times more frequent. Liver cirrhosis was 13 times more frequent. These three conditions account for the vast majority of hemochromatosis-related deaths.
Liver cancer alone is responsible for roughly 30% of deaths in hemochromatosis patients. This risk persists even after iron levels have been brought down to normal, particularly in patients who already had cirrhosis before treatment began. That’s why ongoing liver surveillance with ultrasound every six months is standard for anyone with hemochromatosis-related cirrhosis.
Heart Failure From Iron Deposits
Iron can accumulate directly in heart muscle, weakening its ability to pump blood. Early on, this may cause no symptoms at all. As it progresses, patients develop shortness of breath, fatigue, and swelling in the legs. In severe cases, the heart becomes so weakened that it no longer responds to treatment. Average survival with severe iron overload cardiomyopathy is less than one year.
Heart involvement is more common in people who receive frequent blood transfusions for other conditions, but it also occurs in hereditary hemochromatosis when iron levels climb high enough. The heart can be affected on both sides, and iron can even deposit in the tissue surrounding the heart.
Liver Damage and Cirrhosis
The liver bears the heaviest burden because it’s the primary iron storage organ. Cirrhosis, where scar tissue replaces functioning liver cells, develops in 20 to 45% of people with the most common hemochromatosis gene mutation when their ferritin (a blood marker of iron stores) exceeds 1,000 ng/mL. For context, normal ferritin is typically under 300 for men and under 200 for women.
The five-year survival rate for untreated hemochromatosis patients with cirrhosis drops by 50% compared to those without cirrhosis. Once cirrhosis is established, it doesn’t fully reverse even with treatment, and the elevated liver cancer risk remains for life.
Diabetes From Pancreatic Iron
Iron deposits in the pancreas damage the cells that produce insulin, leading to what’s sometimes called “bronze diabetes” (named for the skin darkening that often accompanies it). About 50% of people who carry two copies of the hemochromatosis gene develop diabetes. This adds its own set of complications, from cardiovascular disease to kidney damage, compounding the mortality risk from hemochromatosis itself. Diabetes caused by iron overload was seven times more frequent as a cause of death compared to age-matched healthy individuals.
Removing excess iron can improve insulin sensitivity, but it doesn’t always reverse established diabetes completely.
Who Is Most at Risk of Dying
Not everyone with the hemochromatosis gene develops dangerous iron overload. About 28% of men who carry two copies of the C282Y mutation (the most common genetic cause) develop iron-related symptoms during their lifetime. Roughly 1 in 10 male carriers will develop severe liver disease unless iron overload is caught and treated early. Women are partially protected before menopause because menstruation removes iron monthly, but risk increases after menopause.
The timing of diagnosis matters enormously. Patients diagnosed before cirrhosis develops and treated with regular blood removal (phlebotomy) have a life expectancy identical to the general population. Patients diagnosed after severe organ damage has already occurred face a life expectancy of less than two years.
How Treatment Prevents Death
Phlebotomy, the regular removal of blood to drain iron stores, is the primary treatment. Each session removes about 250 mg of iron. Initially, sessions happen weekly or biweekly until ferritin levels drop to a target range. After that, maintenance sessions every few months keep iron from building back up.
Treatment guidelines recommend starting phlebotomy when ferritin exceeds 300 ng/mL in adult men and 200 ng/mL in women of childbearing age who are pregnant, or 500 ng/mL in non-pregnant women of childbearing age. The earlier treatment begins, the better the outcomes. Early phlebotomy can reverse liver scarring that hasn’t yet progressed to full cirrhosis, improve insulin sensitivity, reduce skin discoloration, and relieve fatigue. Cirrhosis, joint disease, and hormonal problems are less likely to improve.
Screening is straightforward. A blood test measuring transferrin saturation (how much of the blood’s iron-carrying protein is loaded with iron) catches nearly all cases when a cutoff of 45% is used. If that’s elevated, genetic testing confirms whether hemochromatosis is the cause. Because the condition is common in people of Northern European descent and completely treatable when caught early, testing is worth pursuing if you have a family history or unexplained symptoms like fatigue, joint pain, or elevated liver enzymes.